Rekor posts 35% Q3 revenue growth, but cash burn and financing risks persist. Click here to read analysis of REKR stock now.
Polish diagnostician Dr. Jaroslaw Wilczynski says to look beyond symptoms, analyze the data and admit where things go wrong ...
Get the latest on Tectonic Therapeutic, Inc.'s clinical progress in pulmonary hypertension and market potential. Click for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback